Repare Therapeutics Inc (RPTX) Long-Term Debt to Capital Ratio

Repare Therapeutics - graphic logo of issuer RPTX

Repare Therapeutics (RPTX) is developing partnerships to explore synthetic lethality in oncology. This debt-to-equity chart captures a pivot driven by the implementation of SNIPRx software for identifying genetic vulnerabilities and the active attraction of Big Pharma investments through R&D contracts. The latest parameter stands at 0.00, demonstrating the business's current level of dependence on external creditors.

Long-Term Debt to Equity: Repare Therapeutics (RPTX) for 07/04/2022 - 02/07/2026

Analytical breakdowns for Repare Therapeutics

- market price and analyst price targets:
Market Price Repare Therapeutics, Inc.|RPTX - Price Target Chart
- market capitalization details:
Market Capitalization Repare Therapeutics Inc.|RPTX - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Repare Therapeutics|RPTX - Company Book Value|Market-to-Book Ratio reparerx.com|RPTX - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Repare Therapeutics|RPTX - Long-Term Debt to Equity|Current Liabilities to Capital reparerx.com|RPTX - Company Aggregate Debts|Debt to Net Assets Repare Therapeutics Inc.|RPTX - Company Long-Term Liabilities|Short-Term Debt Repare Therapeutics|Intermediate Coverage Ratio reparerx.com
- company profitability and valuation multiples indicators:
RPTX - Net Income
Summary company analysis:RPTX - Repare Therapeutics, Inc.
Brand item of Repare Rx

Developing oncology drugs requires significant investment before receiving royalties from Roche. This long-term capital structure metric compares liabilities with maturities exceeding one year against equity. A decrease in this ratio indicates a minimization of the debt load. This chart allows for an assessment of Repare Therapeutics (RPTX) funding stability without the risk of bankruptcy. Low leverage confirms financial autonomy and investor confidence in the capital.

Competing companies

Long-Term Liabilities to Capital Genmab AS GMAB|Long-Term Debt to Equity Exelixis Corp (EXEL)|Nuvalent Therapeutics - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KYMR (Kymera Therapeutics)|IDYA - Long-Term Debt to Equity Ratio|ELVN - Long-Term Debt to Equity|Long-Term Liabilities to Capital ORIC Pharmaceuticals Inc|Relay Pharma (RLAY) - Long-Term Debt to Equity|NRIX (Nurix Corp) - Long-Term Debt to Equity|Long-Term Debt to Equity Tyra Biosciences, Inc.|Long-Term Liabilities to Capital verastem.com VSTM|Long-Term Debt to Capital GLUE|Cullinan Oncology (CGEM) - Long-Term Indebtedness to Equity|Immuneering Inc. - Long-Term Debt to Equity Ratio|C4 Therapeutics Corp (CCCC) - Long-Term Liabilities to Capital|BDTX: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient PMVP (pmvpharma.com)|KPTI (karyopharm.com) - Long-Term Debt to Equity Ratio|PPCB: Long-Term Loans to Capital Ratio|BGMS (Cyclacel Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital Aadi Bio|Long-Term Debt to Equity Aileron Therapeutics (ALRN)|BPMC (blueprintmedicines.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital GLYC (GlycoMimetics)|Long-Term Indebtedness to Equity SpringWorks Therapeutics Inc.